Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.

Zanchetta, J R; Bogado, C E

Zanchetta, J R; Bogado, C E.

Affiliation

Zanchetta JR; Instituto de Investigaciones Metabolicas and USAL University School of Medicine, Buenos Aires, Argentina.

J Bone Miner Res ; 16(1): 189-90, 2001 Jan.

Article in En | MEDLINE | ID: mdl-11149484

Subject(s)

Hyperparathyroidism/complications; Osteoporosis, Postmenopausal/complications; Osteoporosis, Postmenopausal/drug therapy; Raloxifene Hydrochloride/therapeutic use; Aged; Alkaline Phosphatase/blood; Bone Density/drug effects; Calcium/blood; Calcium/urine; Creatinine/urine; Female; Femur Neck/drug effects; Femur Neck/metabolism; Humans; Hyperparathyroidism/blood; Lumbar Vertebrae/drug effects; Lumbar Vertebrae/metabolism; Middle Aged; Osteoporosis, Postmenopausal/blood; Osteoporosis, Postmenopausal/metabolism; Parathyroid Hormone/blood; Phosphates/blood; Raloxifene Hydrochloride/administration & dosage; Raloxifene Hydrochloride/pharmacology; Selective Estrogen Receptor Modulators/administration & dosage; Selective Estrogen Receptor Modulators/pharmacology; Selective Estrogen Receptor Modulators/therapeutic use; Time Factors

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis, Postmenopausal / Raloxifene Hydrochloride / Hyperparathyroidism Limits: Aged / Female / Humans / Middle aged Language: En Journal: J Bone Miner Res Journal subject: METABOLISMO / ORTOPEDIA Year: 2001 Document type: Article Affiliation country: Argentina Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links